Advertisement
MTD vs TMO
Which Stock Would AI Choose? Mettler-Toledo International (MTD) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Different scale, similar toolkit. Thermo Fisher Scientific (TMO) is a diversified life-sciences and biopharma-services giant with annual revenue above $45 billion, while Mettler-Toledo (MTD) is a focused precision-instruments specialist with annual revenue around $4 billion.
- Relative performance has diverged. TMO has posted strong multi-month momentum, whereas MTD has recovered from an earlier year-to-date decline but trades closer to, and in some cases below, analyst price targets.
- Both companies raised 2026 guidance on resilient demand, even as tariffs, currency swings, and a soft academic/government spending backdrop weigh on results.
- Growth drivers differ. TMO leans on bioproduction, clinical research, and recent acquisitions, while MTD is benefiting from bioprocessing, product inspection, and emerging-market demand, particularly in China.
- Sentiment skews toward TMO. Sell-side consensus on TMO is broadly bullish, while MTD carries a more mixed "Hold" consensus despite its own guidance raise and share-repurchase program.
Introduction
Both MTD and TMO operate at the intersection of science, precision measurement, and laboratory workflows, yet their businesses, scale, and market positioning are markedly different. This stock comparison is relevant for investors and traders evaluating relative performance and market positioning within the life-sciences and analytical-instruments sector. One is a nimble, high-margin instruments specialist; the other is a diversified, capital-return-focused industry leader. Understanding how recent market activity, growth catalysts, and sentiment have shaped each name can help readers assess which stock offers a more compelling risk-reward profile in the current environment.
MTD Overview and Recent Performance
MTD, Mettler-Toledo International Inc., manufactures and services precision instruments across laboratory, industrial, and food-retail applications. The company recently reported first-quarter revenue of roughly $947 million, up about 7% on a reported basis (3% in local currency), while adjusted EPS (earnings per share) rose 9% year over year to $8.91. Management raised full-year adjusted EPS guidance to a range of $46.30 to $46.95, implying 8% to 10% growth, and announced an expanded share-repurchase program of up to $875 million.
Recent market activity has been mixed. The stock rallied on the earnings beat and guidance raise, yet the sell-side consensus remains a "Hold," with an average price target modestly below recent trading levels. Sentiment has been shaped by strong bioprocessing and China demand, offset by tariff headwinds (estimated to have reduced operating profit by about 4%) and softer chemical, academic, and European end markets. Investors are also watching the pace of customer equipment-replacement cycles and the recovery in laboratory demand.
TMO Overview and Recent Performance
TMO, Thermo Fisher Scientific Inc., is the world's largest life-sciences tools and services company, spanning laboratory products, analytical instruments, specialty diagnostics, and biopharma services through brands including Patheon and PPD. In its most recent quarter, revenue grew 6% to $11.01 billion, with adjusted EPS up 6% to $5.44, and the company raised its full-year guidance to $24.64 to $25.12 in adjusted EPS on revenue of $47.3 billion to $48.1 billion.
Recent performance has been comparatively strong, with notable multi-month share-price gains and a market capitalization near $250 billion. Catalysts include the Clario acquisition, the Solventum filtration-and-separation purchase, a 10% dividend increase, and a $3 billion buyback completed early in the year. Pharma and biotech demand, particularly bioproduction and clinical research, has been the primary growth engine. Offsetting factors include muted academic and government spending, a softer respiratory season in diagnostics, and currency and tariff pressure on margins.
Trending AI Robots
Tickeron operates a marketplace of hundreds of AI Trading Bots that monitor thousands of different tickers, each running its own trading style, strategy, timeframe, performance statistics, and portfolio of securities. Because no single approach fits every market regime, only a curated selection earns a place in Tickeron's Trending AI Robots section. This page highlights the bots that are currently best aligned with prevailing market conditions, allowing traders to browse vetted strategies rather than sift through the full catalog on their own. If you are comparing names like MTD and TMO, exploring the Trending AI Robots page can help you identify automated approaches that are actively trading these or similarly positioned stocks.
Head-to-Head Comparison
The clearest contrast between the two is scale and diversification. TMO's broad exposure across instruments, consumables, diagnostics, and pharma services gives it multiple, partly offsetting demand streams, while MTD's focused portfolio makes its results more sensitive to swings in laboratory and industrial capital spending. On growth, TMO's organic expansion has been modest (about 1% recently), with acquisitions adding meaningfully to reported revenue, whereas MTD has shown steadier local-currency growth led by China and emerging markets.
Risk profiles also differ. Both face tariffs, currency volatility, and inflation tied to geopolitical disruption, but MTD's higher-margin model and heavy reliance on equipment-replacement cycles introduce cyclical sensitivity, while TMO's breadth cushions individual end-market weakness. From a sentiment standpoint, TMO enjoys a stronger consensus and clearer trend consistency, while MTD's valuation has outpaced the average analyst target, reflecting a more mixed outlook on near-term upside.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative momentum, and the breadth of recent catalysts, Tickeron's AI would likely favor TMO over MTD in the current environment. TMO combines a sustained multi-month uptrend, a broadly bullish sell-side consensus, diversified end-market strength, and multiple capital-return and acquisition tailwinds. MTD offers solid execution, a raised outlook, and an aggressive buyback, but its more mixed analyst sentiment and price relative to consensus targets suggest a less decisive setup. This assessment is probabilistic rather than definitive: both names carry execution and macro risk, and the balance could shift with changes in end-market demand or tariff policy.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MTD is a StrongBuy and TMO is a StrongBuy.
MTD in upward trend: 10-day moving average moved above 50-day moving average on September 24, 2026
The 10-day moving average for MTD crossed bullishly above the 50-day moving average on September 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +1.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where MTD advanced for three days, in 194 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 130 of 224 cases where MTD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 58%.
Bearish Trend Analysis
The 10-day RSI Indicator for MTD moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 22 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 76%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MTD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
MTD broke above its upper Bollinger Band on October 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 3 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 11 (best 1 - 100 worst), indicating outstanding price growth. MTD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MTD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MTD's P/B Ratio (2616.972) is very high in comparison to the industry average of (67.473). P/E Ratio (37.653) is within average values for comparable stocks, (2.957). Projected Growth (PEG Ratio) (2.869) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.798) is also within normal values, averaging (9.775).
TMO's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for TMO turned positive on October 28, 2026. Looking at past instances where TMO's MACD turned positive, the stock continued to rise in 30 of 42 cases over the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on TMO as a result. In 58 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
Following a +2.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in 192 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 132 of 244 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
Bearish Trend Analysis
The 10-day RSI Indicator for TMO moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 19 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 53%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
TMO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.892) is normal, around the industry mean (67.473). P/E Ratio (37.453) is within average values for comparable stocks, (2.957). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock slightly better than average.
MTD | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 41 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 72 | 66 | |
SMR RATING 1..100 | 3 | 60 | |
PRICE GROWTH RATING 1..100 | 11 | 10 | |
P/E GROWTH RATING 1..100 | 32 | 25 | |
SEASONALITY SCORE 1..100 | 16 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (65) in the Medical Specialties industry is somewhat better than the same rating for MTD (99). This means that TMO’s stock grew somewhat faster than MTD’s over the last 12 months.
TMO's Profit vs Risk Rating (66) in the Medical Specialties industry is in the same range as MTD (72). This means that TMO’s stock grew similarly to MTD’s over the last 12 months.
MTD's SMR Rating (3) in the Medical Specialties industry is somewhat better than the same rating for TMO (60). This means that MTD’s stock grew somewhat faster than TMO’s over the last 12 months.
TMO's Price Growth Rating (10) in the Medical Specialties industry is in the same range as MTD (11). This means that TMO’s stock grew similarly to MTD’s over the last 12 months.
TMO's P/E Growth Rating (25) in the Medical Specialties industry is in the same range as MTD (32). This means that TMO’s stock grew similarly to MTD’s over the last 12 months.
| MTD | TMO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 76% | 1 day ago 53% |
| Stochastic ODDS (%) | 1 day ago 60% | 1 day ago 62% |
| Momentum ODDS (%) | N/A | 1 day ago 66% |
| MACD ODDS (%) | N/A | 1 day ago 71% |
| TrendWeek ODDS (%) | 1 day ago 61% | 1 day ago 62% |
| TrendMonth ODDS (%) | 1 day ago 60% | 1 day ago 63% |
| Advances ODDS (%) | 3 days ago 61% | 3 days ago 62% |
| Declines ODDS (%) | 6 days ago 67% | 9 days ago 62% |
| BollingerBands ODDS (%) | 1 day ago 73% | 1 day ago 57% |
| Aroon ODDS (%) | 1 day ago 58% | 1 day ago 54% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MTD’s FA Score shows that 3 FA rating(s) are green while TMO’s FA Score has 2 green FA rating(s).
- MTD’s FA Score: 3 green, 2 red.
- TMO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MTD’s TA Score shows that 3 TA indicator(s) are bullish while TMO’s TA Score has 4 bullish TA indicator(s).
- MTD’s TA Score: 3 bullish, 4 bearish.
- TMO’s TA Score: 4 bullish, 4 bearish.
Price Growth
MTD (@Medical Specialties) experienced а +0.27% price change this week, while TMO (@Medical Specialties) price change was +3.44% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +2.12%. For the same industry, the average monthly price growth was -4.89%, and the average quarterly price growth was +48.45%.
Reported Earning Dates
MTD is expected to report earnings on Nov 05, 2026.
TMO is expected to report earnings on Feb 04, 2027.
Industries' Descriptions
@Medical Specialties (+2.12% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
MTD and
Correlation & Price change
A.I.dvisor indicates that over the last year, MTD has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if MTD jumps, then A could also see price increases.
| Ticker / NAME | Correlation To MTD | 1D Price Change % | ||
|---|---|---|---|---|
| MTD | 100% | -2.55% | ||
| A - MTD | 68% Closely correlated | -3.47% | ||
| BRKR - MTD | 67% Closely correlated | -7.95% | ||
| TMO - MTD | 62% Loosely correlated | -1.72% | ||
| AZTA - MTD | 61% Loosely correlated | -5.35% | ||
| RGEN - MTD | 58% Loosely correlated | -6.20% | ||
More | ||||